Extended Data Fig. 7: In inflammation-induced pre-eclampsia, VEGF mRNA LNP 55 partially restores a healthy immune landscape in the blood and placenta.
From: Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
a–c, Immunophenotyping was performed to evaluate differences in the proportion of immune cell populations in the (a) blood, (b) spleen, and (c) placenta in inflammation-induced pre-eclampsia following administration of the VEGF mRNA LNP 55 therapeutic. The proportion of immune cells are reported as mean ± s.e.m. (n = 8 biological replicates). Ordinary two-sided, one-way (a–b) or nested two-sided, one-way (c) ANOVAs with post hoc Student’s t tests using the Holm-Šídák correction for multiple comparisons were used to compare responses across treatment groups.
